Furthermore, the percentage of circulating CD14+CD16+ cells did not decrease in most of the patients experiencing therapeutic regimens in comparison with NDMM patients both with or without active bone disease, except for PD MM patients with active bone disease. The gene discussed is CD14; the disease is Miyoshi myopathy.